US Patent Issued to PHARMASSIST on Aug. 19 for "Method of determining PIK3CA mutational status in a sample" (Greek Inventors)

ALEXANDRIA, Va., Aug. 20 -- United States Patent no. 12,391,985, issued on Aug. 19, was assigned to PHARMASSIST LTD (Athens, Greece).

"Method of determining PIK3CA mutational status in a sample" was invented by Evrykleia Lianidou (Athens, Greece) and Athina Markou (Athens, Greece).

According to the abstract* released by the U.S. Patent & Trademark Office: "An ultra-sensitive, specific methodology for detecting PIK3CA mutations in biological samples of cancer patients, comprises a combination of allele-specific, asymmetric rapid PCR and melting analysis in a DNA sample from Circulating Tumor Cells, cell-free DNA in plasma/serum, or Formalin-Fixed Paraffin-Embedded tissues. Using the allele-specific primers for hotspot mutations in exons 9 ...